[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colonic-polyps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colonic-polyps":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,72,99,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100599832","prospective-open-label-non-significant-risk-multicenter-study-comparing-the-polyp-detection-of-the-study-device-to-that-of-the-colonoscopy-reference-100599832",false,"NCT07089615","Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference","Prospective, Open Label, Pivotal Study of the Accuracy of the CapsoCam® Colon (CV-3) in Detecting Colonic Polyps, Using Colonoscopy as the Reference","Inclusion Criteria:\n\n1. 45-75 years of age\n2. Committed to undergo a colonoscopy.\n3. Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor\n\nExclusion Criteria:\n\n1. Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps\n2. Has contraindication for capsule endoscopy or colonoscopy\n3. Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome\n4. Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease\n5. History of incomplete colonoscopy\n6. Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C\\>6.4 within the past 3 months and\u002For with history of constipation or gastroparesis).\n7. Impaired cardiac function assessed as greater than NYHA Class II\n8. History of small- or large-bowel obstructive condition\n9. Known history of swallowing disorder, and\u002For ischemic bowel disease neuropathies and\u002For radiation enteritis\n10. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention\n11. Known allergy to ingredients used in bowel preparation and boosters\n12. Daily and\u002For regular narcotic use\n13. Decompensated cirrhosis\n14. Prior abdominal radiation therapy\n15. Diagnosis of anorexia or bulimia\n16. History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation\n17. Known or suspected megacolon\n18. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule\n19. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis\n20. Pregnant or nursing or of child-bearing potential and does not agree to practice medically acceptable methods of contraception. Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at screening.\n21. Unable to follow or tolerate fasting, bowel preparation, and other study procedures\n22. Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results\n23. Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study\n24. Chronic constipation as defined by \\\u003C3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements","ALL","45 Years","75 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24],"NA","Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied.\n\nThe purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference.\n\nThe participant will:\n\n1. prep for and swallow a study capsule and then\n2. prep for and undergo a colonoscopy either the following day or 3-6 weeks later",[27],"Colonic Polyps","RECRUITING","2026-05-05",{"date":31,"type":32},"2026-05-08","ACTUAL",{"date":34,"type":32},"2025-06-26",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Capso Vision, Inc.","INDUSTRY",11,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100589638","a-prospective-study-to-evaluate-the-performance-of-a-real-time-system-in-the-estimation-of-colorectal-polyp-size-100589638","NCT06957015","A Prospective Study to Evaluate the Performance of a Real-time System in the Estimation of Colorectal Polyp Size","EndoAIM","Inclusion Criteria:\n\nSubjects are eligible if:\n\n1. They have received colonoscopy for screening, surveillance or symptom investigation;\n2. Aged 18 years older or above;\n3. Written informed consent obtained.\n\nExclusion Criteria:\n\nSubjects are excluded if they have:\n\n1. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)\n2. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)\n3. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)",true,"18 Years",{"count":51,"type":21},278,[24],"Colorectal polyp size is related to the risk of exhibiting advanced histological features. Moreover, polyps larger than 10 mm are associated with an elevated risk of metachronous advanced neoplasia and colorectal cancer (CRC). Consequently, accurate measurement of polyp size, especially at the 10 mm threshold is critical for risk stratification and surveillance intervals. Furthermore, polyp size is also important for the choice of the appropriate resection procedures. Underestimation may lead to delayed diagnosis, thereby increasing the risk of colorectal cancer, while overestimation may result in unnecessary surveillance endoscopies.",[27,55,56],"CRC (Colorectal Cancer)","Artificial Intelligence (AI)",[58,59,60],"artificial intelligence","polyp size measurement","surveillance intervals","2026-04-20",{"date":63,"type":32},"2026-04-23",{"date":65,"type":32},"2025-05-13",{"date":67,"type":21},"2028-01-01",{"name":69,"class":70},"Chinese University of Hong Kong","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":71},"100628921","the-long-term-effect-of-artificial-intelligence-assisted-colonoscopy-on-risk-of-metachronous-advanced-colonic-lesion-100628921","NCT07467928","The Long-term Effect of Artificial Intelligence-assisted Colonoscopy on Risk of Metachronous Advanced Colonic Lesion","Inclusion Criteria:\n\n* Eligible participants are those who were previously enrolled and completed our randomized controlled trial comparing AI-assisted and conventional colonoscopy\n\nExclusion Criteria:\n\n* In addition to the baseline exclusion criteria of the index trial, patients who were found to have inflammatory bowel disease, colorectal cancer and underwent bowel resection would be excluded. Similar to index trial, patients who have developed severe comorbid illnesses that make surveillance colonoscopy and polypectomy unsafe, or become unable to provide informed consent for trial participation would also be excluded\n\nIndex trial: Lui TK, Lam CP, To EW, Ko MK, Tsui VWM, Liu KS, et al. Endocuff With or Without Artificial Intelligence-Assisted Colonoscopy in Detection of Colorectal Adenoma: A Randomized Colonoscopy Trial. Am J Gastroenterol. 2024;119(7):1318-25",{"count":79,"type":21},404,[24],"The goal of this prospective study is to to evaluate the prevalence of metachronous advanced colonic lesions in subsequent surveillance colonoscopies in patients who had previously undergone AI-assisted colonoscopy to conventional colonoscopy examinations.\n\nThe main question it aims to answer is whether employing AI-assisted colonoscopy can decrease the likelihood of metachronous advanced colonic lesions during subsequent surveillance colonoscopies.\n\nResearchers will compare patient who undergo conventional colonoscopy in previous colonoscopy to see if AI-assisted colonoscopy can decrease the likelihood of metachronous advanced colonic lesions during subsequent surveillance colonoscopies. Participants will undergo surveillance colonoscopy to assess the presence of metachronous advanced colonic lesion",[27,83,84],"Artifical Intelligence","Advanced Metachonous Colonic Lesion",[86,87,88,89],"Colonic polyps","Artificial intelligence","Surveillance colonoscopy","advanced metachonous colonic lesion","2026-03-08",{"date":92,"type":32},"2026-03-12",{"date":94,"type":32},"2025-07-01",{"date":96,"type":21},"2028-02-28",{"name":98,"class":70},"The University of Hong Kong",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":71},"100589956","linked-color-imaging-versus-indigo-carmine-pump-spraying-on-the-colorectal-adenoma-detection-rate-100589956","NCT06961149","Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate","Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate: a Prospective , Randomized Controlled, Non-inferiority Study","Inclusion Criteria:\n\n1. Age between 45 and 85 years\n2. Patients with a history of colorectal adenoma\n3. Patients whose first-degree relatives have a history of colorectal cancer or colorectal adenoma\n4. Patients with gastrointestinal symptoms (abdominal pain, bloody stool, chronic diarrhea or constipation, Unexplained anemia or weight loss;\n5. Patients with positive Fecal Immunochemical Test\n\nExclusion Criteria:\n\n1. Patients with pregnancy, inflammatory bowel disease, familial adenomatosis polyposis, suspected CRC; intestinal obstruction, coagulopathy\n2. Patients with aspirin, clopidogrel or other anticoagulants\u002F antiplatelet drugs intake within 7 days\n3. Patents previous colorectal resection\n4. Patients with failed cecal intubation\n5. Patients with inadequate bowel preparation quality (BBPS≤5)\n6. Patients who refuse to participate or to provide informed consent","85 Years",{"count":108,"type":21},352,[24],"Detection and removal of polyps during colonoscopy is crucial for the prevention of colorectal cancer. Indigo carmine spraying up to the colonic mucosa could probably increase the adenoma detection rate, but considering the long withdrawal time of the endoscope and the resulting increase in time and cost. Linked-color imaging (LCI) is a newly developed image-enhanced endoscopy technology. It relies on wave length optimization of three colors (red, green, and blue) to make the lesions appear fuller. LCI improves the visibility of colorectal adenomas and polyps and may increase the detection rate of lesions. In order to explore the clinical application value of Linked-color imaging endoscopy, we performed a prospective, randomized controlled trial to compare adenoma detection rate of Linked-color imaging endoscopy and indigo carmine chromoendoscopy.",[27,112,113,114,115],"Adenomatous Polyps","Adenoma Detection Rate","Chromoendoscopy","Colorectal Neoplasms",[113,117,114,118,119],"Linked-color imaging","Colonoscopy","Indigo Carmine","2025-05-05",{"date":122,"type":32},"2025-05-07",{"date":124,"type":32},"2025-04-08",{"date":126,"type":21},"2026-04-01",{"name":128,"class":70},"Shandong University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":106,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100576924","surveillance-intervals-after-piecemeal-resection-of-non-pedunculated-colorectal-lesions-20mm-100576924","NCT06791616","Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm","Evaluation of Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm: SCARFACE Clinical Trial","Inclusion Criteria:\n\n* Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.\n* Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Resection performed using a cold snare technique due to the high risk of recurrence.\n* Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.\n* Absence of information regarding the grade of dysplasia of the index lesion.\n* Personal history of colorectal cancer.\n* Incomplete endoscopic resection of the index lesion or any other polyps present in the patient.\n* When the endoscopist performing the index colonoscopy expresses doubts about whether the resection was complete.\n* Index lesion with prior attempted resection.\n* Hereditary cancer syndromes (e.g., adenomatous or serrated polyposis syndromes, Lynch syndrome, etc.).\n* Inflammatory bowel disease.\n* Severe comorbidities with reduced life expectancy.\n* Pregnancy.\n* Ongoing cytotoxic treatment or radiotherapy for a malignant disease.",{"count":137,"type":21},746,[24],"Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.\n\nThe multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.\n\nPatients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.",[115,141,27,142,143,144,145,146],"Adenoma Colon","Serrated Adenoma","Endoscopic Mucosal Resection","Non-pedunculated Lesions","Thermal Ablation","Recurrence","NOT_YET_RECRUITING","2025-01-19",{"date":150,"type":32},"2025-01-24",{"date":152,"type":21},"2025-03-01",{"date":154,"type":21},"2030-05-31",{"name":156,"class":70},"Asociación Española de Gastroenterología"]